Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment증례 보고: SARS-CoV-2 감염이 오래 지속된 APDS 환자 1명에서 단일클론항체로 성공적인 치료Case Reports Published on 2022-06-212022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] activated activated PI3K delta syndrome (APDS) administration affected APDS clearance COVID19 described Efficacy first positive genotyping IEI Infection LINE long-lasting long-lasting infection monoclonal monoclonal antibodies monoclonal antibody multiple therapeutic agent multiple therapeutic agents neutralizing monoclonal antibodies other treatments Patient pauci-symptomatic PI3K Prolonged reducing Remdesivir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus Swab syndrome tested the SARS-CoV-2 virus therapeutic agents Tolerability treated Viral viral shedding virus wild type [DOI] 10.3389/fimmu.2022.891274 PMC 바로가기 [Article Type] Case Reports
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response회복기 혈장의 항체는 내인성 항체 반응이 있거나 없는 개인에서 SARS-CoV-2 제거를 촉진합니다Clinical Trial Published on 2022-06-152022-09-11 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI absence Adaptive immunity adjusted hazard ratio adverse events affected antibody Antibody Response clearance Clinical research Comorbidity Comprehensive conducted convalescent plasma Convalescent plasma therapy Corona COVID-19 Critical demonstrated disease status Efficacy evidenced faster hazard ratio hospitalized COVID-19 patient human infection human infections Immunotherapy individual Innovation Intervention IQR Kaplan-Meier analysis laboratory parameter median interval Mortality neutralization Neutralizing neutralizing antibody onset of symptom parameter Phase I plasma plasma therapy pool principle priority Program promote recipient recipients Red respond Safe SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 clearance SARS-CoV-2 vaccines serological significantly survival therapeutic Therapeutics therapy transfusion-related adverse event transfusion-related adverse events Trial university University of Zurich Viral viral clearance Viral load Viremia Virological virus clearance [DOI] 10.1172/JCI158190 PMC 바로가기 [Article Type] Clinical Trial
Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 EvolutionObservational Study Published on 2022-06-132022-10-05 Journal: International Journal of Molecular Sciences [Category] 임상, [키워드] Analysis analyzed association Benign Cell clearance complex conducted Control COVID-19 COVID-19 patient cytotoxic activity degranulation degranulation activity early stage Essential Evolution expression form forms granzymes healthy control hospital identify Immune cell immunological profile independent risk factor Infection Innate innate immune cell Innate immunity natural natural killer natural killer. NK cell NKG2D NKT cell non-severe patient outcome Patient prospective observational study protective factor severe patients severity subjects subpopulation the disease the healthy [DOI] 10.3390/ijms23126577 PMC 바로가기 [Article Type] Observational Study
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI TrialRandomized Controlled Trial Published on 2022-06-012022-10-05 Journal: Advances in therapy [Category] COVID19(2023년), SARS, 임상, [키워드] breath clearance clinical status COVID-19 double-blind Dyspnoea ELOM-080 enhancement enhancer enrolment EudraCT evaluated exploratory exploratory study had no hospitalisation hospitalised IMPROVE Inflammatory less MCC MCC enhancement Mucociliary clearance Patient patients treated patients with COVID-19 per-protocol Placebo PPS Prospective randomised recruitment required respiratory respiratory diseases Safety Shortness of breath. significant effect supplemental oxygen the placebo group therapy treat treating COVID-19 Trial [DOI] 10.1007/s12325-022-02135-z PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal ModelsSARS-CoV-2에 대한 결합된 근육내/비강내 RAZI-COV PARS 백신 후보의 안전성 및 효능: 여러 동물 모델에서의 전임상 연구Article Published on 2022-05-262022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence adjuvant administration Against Amino acid animal approval BALB/c mice blood chemistry candidate candidate vaccine Cellular immune response changes in clearance Combined control group COVID-19 different dose dose Efficacy Efficacy and safety evaluated hamster hamsters heterologous prime-boost High dose humoral IgA antibody immune immune response Immunity induce interval intramuscular intranasal intranasally Iran lung Lung pathology Lungs mice middle Model Modification monomeric mucosal N-terminal domain Neutralizing antibodies New NTD organs parameters Pathological examination pfu Placebo Preclinical Protective RAZI-COV PARS RBD regimens repeated robust Safety SARS-CoV-2 SARS-CoV-2 preclinical study SARS-CoV-2 spike protein significantly specific IgG antibody Spike protein Spread stimulated subunits tested the vaccine trimer vaccination Vaccine vaccine candidate viral infection virus virus load was performed [DOI] 10.3389/fimmu.2022.836745 PMC 바로가기 [Article Type] Article
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosusClinical Science Published on 2022-05-162024-09-04 Journal: Rheumatology (Oxford, England) [Category] 대상포진, [키워드] anifrolumab Autoimmunity biologic therapies clearance Efficacy Exposure–response Population pharmacokinetics Safety systematic lupus erythematosus [DOI] 10.1093/rheumatology/keab704 PMC 바로가기 [Article Type] Clinical Science
Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metricsSARS-CoV-2 PCR 및 혈청학적 역학적 지표에 내재된 편향 분석Observational Study Published on 2022-05-132022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody detection basic reproduction number bias caution Chain Reaction clearance conducted coronavirus Course cross-sectional survey Cross-sectional surveys detectable develop diagnose Effect Epidemic epidemic peak Epidemics epidemiological estimation incidence Infection Inference inherent biase investigated mathematical mathematical model Measures Metrics MONITOR Observational data outcome PCR PCR positivity PCR testing polymerase chain polymerase chain reaction populations positive predicted Prevalence progression Prospective respiratory SARS-CoV-2 SARS-CoV-2 PCR serological Serological testing Seroprevalence severe acute respiratory syndrome Coronavirus tested [DOI] 10.1186/s12879-022-07425-z PMC 바로가기 [Article Type] Observational Study
Association of Gut Microbiota with Inflammatory Bowel Disease and COVID-19 Severity: A Possible Outcome of the Altered Immune Response염증성 장 질환 및 COVID-19 중증도와 장내 미생물총의 연관성: 변경된 면역 반응의 가능한 결과Review Published on 2022-05-052022-09-11 Journal: Current microbiology [Category] COVID19(2023년), SARS, 치료제, [키워드] alteration Altered Antiviral antiviral immune response ARDS Bacteroidaceae bowel Brain Cell chemokine chemokines circulation clearance COVID-19 COVID-19 patient cytokine Cytokine storm Cytokines disease Disease progression dominant drastic Dysbiosis dysfunction Enterococcus event events excessive secretion Fecal sample fecal samples Gut gut microbiome gut microbiota gut-lung axis Health help homeostasis hospitalized patients hyper inflammation immune immune cells immune dysfunction immunological impair Inflammatory bowel disease invading pathogen invading pathogens involved kidney Lungs metabolite metabolites Microbiome microorganism microorganisms modulated mucosal organ Pathogens physiological poor prognosis Presence replaced respiratory tract respiratory viral infection response SARS-CoV-2 severity Signaling Staphylococcus stimulate Streptococcus the cytokine storm viral infection Viral RNA virus [DOI] 10.1007/s00284-022-02877-7 PMC 바로가기 [Article Type] Review
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso부르키나파소에서 하이드록시클로로퀸 또는 클로로퀸과 아지트로마이신 조합으로 치료한 COVID-19 입원 환자 및 외래 환자의 회복 시간, 악화 및 사망 평가Observational Study Published on 2022-05-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 95% CI adjusted aggravation assessment association Azithromycin Burkina Faso Chloroquine Chloroquine phosphate clearance death disease dose fatality Follow-up Hydroxychloroquine hydroxychloroquine plus azithromycin information Inpatient Inpatients lower risk multivariable no significant difference no significant differences observational study outcome Outpatient Patient patients with COVID-19 phosphate Poisson model provided receiving retrospective SRAS-CoV-2 statistical time Time to recovery treated Treatment viral clearance Virological with COVID-19 worsening [DOI] 10.1016/j.ijid.2022.02.034 PMC 바로가기 [Article Type] Observational Study
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antiviralsResearch article Published on 2022-05-012022-10-05 Journal: Arab Journal of Gastroenterology [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] addition Antiviral approved clearance Combination COVID-19 COVID-19 infection Cox regression drug Efficacy and safety evaluated Factor Follow-up group highest Infection interval Mild moderate Mortality multicenter negative RT-PCR nitazoxanide Open-label Patient patients with COVID-19 polymerase chain primary endpoint Randomized Randomized controlled trial Result RT-PCR Safe SARS-CoV-2 SCT Serious Adverse Event significantly higher Sofosbuvir/ledipasvir standard care tested therapy three groups Treatment treatment for COVID-19 treatments for COVID-19 viral clearance viral clearance rate was done were recorded [DOI] 10.1016/j.ajg.2022.04.005 [Article Type] Research article